The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the entire programme.
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial / Valgimigli, Marco; Frigoli, Enrico; Leonardi, Sergio; Vranckx, Pascal; Rothenbühler, Martina; Tebaldi, Matteo; Varbella, Ferdinando; Calabrò, Paolo; Garducci, Stefano; Rubartelli, Paolo; Briguori, Carlo; Andó, Giuseppe; Ferrario, Maurizio; Limbruno, Ugo; Garbo, Roberto; Sganzerla, Paolo; Russo, Filippo; Nazzaro, Marco; Lupi, Alessandro; Cortese, Bernardo; Ausiello, Arturo; Ierna, Salvatore; Esposito, Giovanni; Ferrante, Giuseppe; Santarelli, Andrea; Sardella, Gennaro; de Cesare, Nicoletta; Tosi, Paolo; van 't Hof, Arnoud; Omerovic, Elmir; Brugaletta, Salvatore; Windecker, Stephan; Heg, Dik; Jüni, Peter. - In: THE LANCET. - ISSN 0140-6736. - 392:10150(2018), pp. 835-848-848. [10.1016/S0140-6736(18)31714-8]
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Esposito, Giovanni;
2018
Abstract
The Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of radial versus femoral access and of bivalirudin versus unfractionated heparin with optional glycoprotein IIb/IIIa inhibitors in patients with the whole spectrum of acute coronary syndrome undergoing invasive management. Here we describe the prespecified final 1-year outcomes of the entire programme.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
